AN2 Therapeutics, Inc. - Common Stock (NQ:ANTX)

5.710 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AN2 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 04, 2024

Via Benzinga

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023 ↗

March 28, 2024

ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

March 28, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 13, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Nasdaq Edges Lower; ContextLogic Shares Surge ↗

February 12, 2024

U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow traded up 0.52% to 38,873.28 while the NASDAQ fell 0.10% to 15,975.16. The...

Via Benzinga

Topics Stocks

Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

February 12, 2024

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 12, 2024

Via Benzinga

Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B ↗

February 12, 2024

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500...

Via Benzinga

Topics Stocks

US Stocks Mixed; Trimble Issues Weak Outlook ↗

February 12, 2024

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.05% to 38,651.80 while the NASDAQ rose...

Via Benzinga

Topics Stocks

Why Is Infectious Disease-Focused AN2 Therapeutics Stock Sinking Today? ↗

February 12, 2024

AN2 Therapeutics pauses Phase 3 enrollment for epetraborole trial in Mycobacterium Avium Complex lung disease. Updates expected in summer 2024.

Via Benzinga

Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

February 12, 2024

U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 45 points on Monday. Shares of monday.com Ltd. (NASDAQ: MNDY) fell sharply in today’s pre-market trading after...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 12, 2024

Via Benzinga

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

February 12, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

January 30, 2024

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

November 09, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at Upcoming Investor Conferences

November 06, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

October 18, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

October 11, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria

September 26, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease

September 13, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

Top 5 Health Care Stocks That May Fall Off A Cliff ↗

September 06, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

$16M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying ↗

August 23, 2023

Although U.S. stocks closed mostly lower on Tuesday, there were a few notable insider trades.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 17, 2023

Via Benzinga

AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock

August 15, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

August 10, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at Jefferies Healthcare Conference

May 25, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 16, 2023

Via Benzinga

AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

May 11, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics to Present at JMP Securities Life Sciences Conference

May 01, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

March 29, 2023

From AN2 Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.